

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

COMPLETE VERSION OF ALL PENDING CLAIMS

WHAT IS CLAIMED IS:

1. (Amended) A pharmaceutical composition for the treatment of sinusitis comprising a therapeutically effective amount of a peptide having a C-terminal sequence amino acid sequence KPV (SEQ ID NO:1) in combination with a therapeutically effective amount of a decongestant/antihistamine.
2. (Amended) The pharmaceutical composition of claim 1 wherein the peptide is selected from the group of peptides with a C-terminal amino acid sequence consisting of: KPV (SEQ ID NO:1), VPK-Ac-CC-Ac-KPV, HFRWGKPV (SEQ ID NO:2) and SYSMEHFRWGKPV (SEQ ID NO:3).
3. The composition of claim 1 wherein said decongestant/antihistamine is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chlorpheniramine, brompheniramine, pheniramine and loratidine.
4. The composition of claim 1 further comprising a therapeutically effective amount of an antibiotic.
5. The composition of claim 4 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithromycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and azithromycin.

6. The composition of claim 1 further comprising a therapeutically effective amount of a glucocorticosteroid.
7. The composition of claim 6 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, triamcinolone.
8. The composition of claim 1 further comprising a therapeutically effective amount of a fungicide.
9. The composition of claim 8 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.
10. The pharmaceutical composition of claim 1 further contained in a carrier.
11. The composition of claim 10 wherein the concentration of said peptide is at least 10^{-12} M.
12. The composition of claim 11 wherein the carrier is selected from the group consisting of: saline, phosphate buffered saline, gelatin maltodextrin, cellulose, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose and hydroxymethyl cellulose with glycerin.
13. (Amended) A pharmaceutical composition for the treatment of sinusitis comprising a therapeutically effective amount of a peptide having a C-terminal sequence amino acid sequence KPV (SEQ ID NO:1) in combination with a therapeutically effective amount of a decongestant/antihistamine and a therapeutically effective amount of a fungicide.
14. (Amended) The pharmaceutical composition of claim 13 wherein the peptide is selected from the group of peptides with a C-terminal amino acid sequence consisting of: KPV

(SEQ ID NO:1), VPK-Ac-CC-Ac-KPV, HFRWGKPV (SEQ ID NO:2) and
SYSMEHFRWGKPV (SEQ ID NO:3).

15. The composition of claim 13 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.

16. The composition of claim 13 further comprising application of a therapeutically effective amount of an antibiotic.

17. The composition of claim 16 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithromycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and azithromycin.

18. The composition of claim 13 further comprising a therapeutically effective amount of a glucocorticosteroid.

19. The composition of claim 18 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, triamcinolone.

20. The composition of claim 13 wherein said antihistamine/decongestant is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chlorpheniramine, brompheniramine, pheniramine and loratidine.

21. The pharmaceutical composition of claim 10 further solvated in a carrier.

22. The composition of claim 21 wherein the concentration of said peptide is at least 10^{-12} M.

23. The composition of claim 21 wherein the carrier is selected from the group consisting of: saline, phosphate buffered saline, gelatin maltodextrin, cellulose, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose and hydroxymethyl cellulose with glycerin.
24. (Amended) A method for the treatment of sinusitis comprising application of a pharmaceutical effective amount of a peptide having a C-terminal sequence amino acid sequence **KPV (SEQ ID NO:1)**.
25. (Amended) The method of claim 24 wherein the peptide is selected from the group with a C-terminal amino acid sequence consisting of KPV (**SEQ ID NO:1**), VPK-Ac-CC-Ac-KPV, HFRWGKPV (**SEQ ID NO:2**) and SYSMEHFRWGKPV (**SEQ ID NO:3**).
26. The method of claim 24 further comprising application of therapeutically effective amount of a fungicide.
27. The method of claim 26 wherein said fungicide is selected consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.
28. The method of claim 24 further comprising application of a therapeutically effective amount of an antibiotic.
29. The method of claim 28 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithromycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and azithromycin.
30. The method of claim 24 further comprising application of a therapeutically effective amount of a decongestant/antihistamine.

31. The method of claim 28 further said decongestant is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chlorpheniramine, bromopheniramine, pheniramine and loratidine.

32. The method of claim 24 further comprising application of a therapeutically effective amount of a glucocorticosteroid.

33. The method of claim 32 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, triamcinolone.

34. The method of claim 24 wherein said peptide is systemically or topically applied before, during or after surgery performed to treat sinusitis.